Skip to Main Content

INFORMATION FOR

Anees Chagpar

MD, MBA, MPH, FACS, FRCS(C)
Professor of Surgery (Oncology, Breast); Affiliated Faculty, Yale Institute for Global Health

Contact Information

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)

Office Location

Mailing Address

  • Surgical Oncology

    20 York St

    New Haven, CT 06510

    United States

Research Summary

Dr. Chagpar's primary research area is in breast cancer. Her work spans from collaborative translational work, to clinical research including large randomized controlled trials, to large database studies involving population science. In addition to specific projects pertaining to breast cancer, she is also passionate about global health and health disparities, and has done extensive work in these areas.

Extensive Research Description

My research interests span from collaborative translational science to clinical research and trials to population science and outcomes research using large databases. My research focus is dedicated to breast cancer, but has touched a number of key themes over the evolution of my career.

  • Chest wall recurrence after mastectomy My early publications focused on the issue of chest wall recurrences after mastectomy – elucidating a simple clinical prediction model to predict prognosis that is used to this day, describing the role of post-mastectomy radiation therapy in reducing recurrence, and finding that reconstruction does not need to be taken down in order to effectively manage chest wall recurrences that occur in autologous flaps.
    1. Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames F, Marcy S, Babiera G, Feig B, Hortobagyi GN, Kuerer HM.“Chest wall recurrence after mastectomy does not always portend a dismal outcome”, Annals of Surgical Oncology 2003; 10(6): 628-634.
    2. Chagpar A, Kuerer HM, Hunt KK, Strom EA, Buchholz TA.“Outcome of breast cancer patients with chest wall recurrence according to initial stage:Implications for post-mastectomy radiation therapy”, International Journal of Radiation Oncology, Biology and Physics 2003; 57(1):128-135.
    3. Chagpar A, Langstein H, Kronowitz S, Singletary SE, Ross MI, Buchholz TA, Hunt KK, Kuerer HM.“Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction”, American Journal of Surgery 2004; 187: 164-169.
  • Sentinel node biopsy Beyond management of local recurrences, the understanding of how to optimally predict prognosis and manage regional disease became increasingly important, as it is known that lymph node status is the key determinant of outcome.I therefore did a number of studies evaluating sentinel node biopsy in breast cancer – identifying the most appropriate technique to use, characterizing the prognostic implications of micrometastases, and ultimately defining clinical prediction models for additional metastases in non-sentinel nodes in sentinel node positive patients.Many of these were seminal works from the largest study of patients who had sentinel node biopsy followed by axillary node dissection, and form the basis of our clinical practice today.
    1. Chagpar A, Martin RC, Chao C, Wong SL, Edwards MJ, Tuttle T, McMasters KM.“Validation of sub- and peri-areolar injection techniques for breast sentinel lymph node biopsy”, Archives of Surgery 2004; 139(6): 614-620.
    2. Chagpar AB, Martin RC, Scoggins CR, Carlson DJ, Laidley AL, El-Eid SE, McGlothin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. “Factors predicting failure to identify a sentinel node in breast cancer”, Surgery 2005; 138(1):56-63.
    3. Chagpar AB, Scoggins CR, Martin RC, Carlson DJ, Laidley AL, El-Eid SE, McGlothin TQ, McMasters KM. “Prediction of sentinel lymph node-only disease in women with invasive breast cancer”,American Journal of Surgery 2006; 192(6):882-887.
    4. Chagpar AB, Camp RL, Rimm DL.“Lymph node ratio should be incorporated into staging for breast cancer”, Annals of Surgical Oncology 2011; 18(11): 3143-8.
  • Screening:Costs and Value As the practice of sentinel node biopsy evolved, it became clear that minimal disease in the axilla did not have the same prognostic implications as more extensive disease.The once tightly held paradigm that we need to find any/all disease early and treat it therefore came under more scrutiny and my attention then turned to the critical evaluation of screening; national trends, the economic impact of this and ultimately, the value it brings in terms of improved outcomes.Some of this work has been used by national organizations, such as the US Preventative Services Task Force, in terms of guiding policy.I led several of these studies looking at data from the National Health Interview Survey, and collaborated on other studies evaluating data from SEER-Medicare with Yale’s Center for Outcomes Public Policy and Effectiveness Research (COPPER).
    1. Chagpar AB, Polk HC, McMasters KM. “Racial trends in mammography rates: A population-based study”, Surgery 2008; 144(3);467-472.
    2. Killelea B, Lannin D, Horvath, L, Chagpar AB.“Factors associated with breast MRI use:A population-based analysis”, Annals of Surgical Oncology 2013; 20(6): 1798-805.
    3. Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X.“The Cost of Breast Cancer Screening in the Medicare Population”, JAMA Internal Medicine 2013; 173(3): 220-6.
  • Margins In keeping with the overarching theme of optimal management of breast cancer and cost/value, our most recent work has been on looking at margins – how we evaluate these intraoperatively, and how we can reduce positive margin and re-excision rates.As a result, we recently completed the largest randomized controlled trial to date regarding the utility of cavity shave margins. We found that, with this technique, we could dramatically reduce the positive margin and re-excision rates for women undergoing partial mastectomy for breast cancer. This was the most rapidly accruing therapeutic clinical trial at Yale Cancer Center, and the data were published in the New England Journal of Medicine. I was the PI on this trial, and led many of the other studies we did on this topic.


    1. Chagpar AB, Killelea B, Tsangaris T, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin D, Pusztai L, Horowitz N. "A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer", N Engl J Med 2015; 373: 503-510.
    2. Chagpar A, Yen T, Whitman G, Sahin A, Hunt KK, Ames F, Ross MI, Meric F, Babiera GV, Singletary SE, Kuerer HM.“Intra-operative margin assessment reduces re-excision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery”, American Journal of Surgery 2003; 186: 371-377.
    3. Chagpar A, Chao, C, Martin RCG, McMasters KM.“Lumpectomy margins are affected by tumor size and histologic subtype, not by biopsy type”, American Journal of Surgery 2004; 188(4):399-402.


Coauthors

Research Interests

Breast Neoplasms; Ethics; Health Services Research; Medical Oncology; Quality of Health Care; Health Care Quality, Access, and Evaluation; Health Care

Public Health Interests

Cancer; Global Health; Health Equity, Disparities, Social Determinants and Justice

Selected Publications

  • Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Nguyen T, Tanasijevic A, Tanasijevic A, Neuhouser M, Neuhouser M, Hershman D, Hershman D, Basen-Engquist K, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.
  • Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.
  • Does perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer?Chagpar A, Qader S, Qader S, Baqri M, Baqri M, Khoshnood K, Ahmed H, Ahmed H. Does perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer? Journal Of Clinical Oncology 2022, 40: e18680-e18680. DOI: 10.1200/jco.2022.40.16_suppl.e18680.
  • Are patients with alcohol-related cancers (ARCs) more likely to quit drinking than the general population? Results of a national population-based survey.Ishani K, Chagpar A. Are patients with alcohol-related cancers (ARCs) more likely to quit drinking than the general population? Results of a national population-based survey. Journal Of Clinical Oncology 2022, 40: e18716-e18716. DOI: 10.1200/jco.2022.40.16_suppl.e18716.
  • Abstract PO-272: Factors associated with HPV vaccine uptake: Insights from those who receive the flu shotRatnasamy P, Chagpar A. Abstract PO-272: Factors associated with HPV vaccine uptake: Insights from those who receive the flu shot Cancer Epidemiology Biomarkers & Prevention 2022, 31: po-272-po-272. DOI: 10.1158/1538-7755.disp21-po-272.
  • HPV vaccination and factors influencing vaccine uptake among people of Indian ancestry living in the United States.Ratnasamy P, Chagpar A. HPV vaccination and factors influencing vaccine uptake among people of Indian ancestry living in the United States. Journal Of Clinical Oncology 2021, 39: 126-126. DOI: 10.1200/jco.2020.39.28_suppl.126.
  • Milestone Studies in Breast Cancer SurgeryChagpar A. Milestone Studies in Breast Cancer Surgery 2021, 9-17. DOI: 10.1007/978-3-030-73147-2_2.
  • ASO Visual Abstract: Debate: Postmastectomy Radiation Therapy in T1/2N1 DiseaseChagpar A. ASO Visual Abstract: Debate: Postmastectomy Radiation Therapy in T1/2N1 Disease Annals Of Surgical Oncology 2021, 28: 648-648. DOI: 10.1245/s10434-021-10689-5.
  • ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation SurgeryChagpar A, Berger E, Alperovich M, Zanieski G, Avraham T, Lannin D. ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery Annals Of Surgical Oncology 2021, 28: 632-632. DOI: 10.1245/s10434-021-10584-z.
  • Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.
  • How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.
  • Abstract PS1-15: Does breast cancer subtype impact margin status in patients undergoing partial mastectomy?Fenton A, Dupont E, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, Chiba A, Berger A, Levine E, Gass J, Gallagher K, Lum S, Martinez R, Willis A, Pandya S, Brown E, Mendiola A, Murray M, Solomon N, Senthil M, Ollila D, Edmonson D, Lazar M, Namm J, Li F, Butler M, McGowan N, Herrera M, Avitan Y, Yoder B, Walters L, McPartland T, Haddad V, Ma H, Xie M, Chagpar A. Abstract PS1-15: Does breast cancer subtype impact margin status in patients undergoing partial mastectomy? Cancer Research 2021, 81: ps1-15-ps1-15. DOI: 10.1158/1538-7445.sabcs20-ps1-15.
  • Abstract PO-240: The effect of emotional disorders on adherence to mammography screening guidelinesYazgan I, Chagpar A. Abstract PO-240: The effect of emotional disorders on adherence to mammography screening guidelines Cancer Epidemiology Biomarkers & Prevention 2020, 29: po-240-po-240. DOI: 10.1158/1538-7755.disp20-po-240.
  • Abstract PO-203: How many breast cancer survivors in America forgo treatment due to cost?Chagpar A. Abstract PO-203: How many breast cancer survivors in America forgo treatment due to cost? Cancer Epidemiology Biomarkers & Prevention 2020, 29: po-203-po-203. DOI: 10.1158/1538-7755.disp20-po-203.
  • Abstract 3502: Do obese patients present with worse breast cancerWang M, Huang J, Chagpar A. Abstract 3502: Do obese patients present with worse breast cancer Cancer Research 2020, 80: 3502-3502. DOI: 10.1158/1538-7445.am2020-3502.
  • Abstract CT281: Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancerFerrer J, Carr D, Wapnir I, Hunt K, Blumencranz P, Dekhne N, Dodge D, Dyess D, Hwang S, Valente S, Clark L, Lesnikoski B, Chagpar A, Clark P, Lee M, Schlossberg B, Madden S, Gjylameti L, Chang M, Smith K, Smith B. Abstract CT281: Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer Cancer Research 2020, 80: ct281-ct281. DOI: 10.1158/1538-7445.am2020-ct281.
  • Is there an association between air pollution levels and lung cancer incidence?Patel S, Chagpar A. Is there an association between air pollution levels and lung cancer incidence? Journal Of Clinical Oncology 2020, 38: e13584-e13584. DOI: 10.1200/jco.2020.38.15_suppl.e13584.
  • Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello T, Blenman K, Rimm D, Silber A. Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) Cancer Research 2020, 80: pd1-01-pd1-01. DOI: 10.1158/1538-7445.sabcs19-pd1-01.
  • Abstract OT3-06-02: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancerSmith K, Ferrer J, Carr D, Blumencranz P, Dodge D, Dekhne N, Wapnir I, Hunt K, Gold L, Valente S, Beitsch P, Dyess D, Hwang S, Clark L, Lesnikoski B, Chagpar A, Karp S, Schlossberg B, Gjylameti L, Smith B. Abstract OT3-06-02: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer Cancer Research 2020, 80: ot3-06-02-ot3-06-02. DOI: 10.1158/1538-7445.sabcs19-ot3-06-02.
  • Abstract P1-20-06: Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trialFerrer J, Carr D, Blumencranz P, Dodge D, Dekhne N, Wapnir I, Hunt K, Gold L, Valente S, Beitsch P, Dyess D, Hwang S, Clark L, Lesnikoski B, Chagpar A, Karp S, Schlossberg B, Madden S, Chang M, Smith K, Strasfeld D, Lee W, Smith B. Abstract P1-20-06: Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trial Cancer Research 2020, 80: p1-20-06-p1-20-06. DOI: 10.1158/1538-7445.sabcs19-p1-20-06.
  • Abstract CT220: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancerSmith K, Ferrer J, Smith B, Hwang E, Hunt K, Dodge D, Karp S, Valente S, Wapnir I, Clark L, Carr D, Beitsch P, Dyess D, Lesnikoski B, Blumencranz P, Dekhne N, Gold L, Chagpar A, Kacena K, Gjylameti L, Geissler F. Abstract CT220: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer 2019, ct220-ct220. DOI: 10.1158/1538-7445.sabcs18-ct220.
  • Abstract CT220: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancerSmith K, Ferrer J, Smith B, Hwang E, Hunt K, Dodge D, Karp S, Valente S, Wapnir I, Clark L, Carr D, Beitsch P, Dyess D, Lesnikoski B, Blumencranz P, Dekhne N, Gold L, Chagpar A, Kacena K, Gjylameti L, Geissler F. Abstract CT220: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer Cancer Research 2019, 79: ct220-ct220. DOI: 10.1158/1538-7445.am2019-ct220.
  • A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study.Sanft T, Harrigan M, Cartmel B, Ferrucci L, Basen-Engquist K, Basen-Engquist K, Hershman D, Hershman D, Ligibel J, Ligibel J, Neuhouser M, Neuhouser M, Chagpar A, Jones B, Knobf M, Silber A, Li F, Irwin M. A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study. Journal Of Clinical Oncology 2019, 37: tps11633-tps11633. DOI: 10.1200/jco.2019.37.15_suppl.tps11633.
  • Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.
  • Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs).Chagpar A, Coccia M. Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs). Journal Of Clinical Oncology 2019, 37: 1566-1566. DOI: 10.1200/jco.2019.37.15_suppl.1566.
  • Abstract CT166: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancerFerrer J, Hwang S, Hunt K, Dodge D, Chagpar A, Grobmyer S, Karp S, Valente S, Wapnir I, Smith K, Ramirez E, Bischof T, Strasfeld D, Lee D, Smith B. Abstract CT166: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer Cancer Research 2018, 78: ct166-ct166. DOI: 10.1158/1538-7445.am2018-ct166.
  • Breast cancer risk perception and adherence to u.s. cancer prevention guidelines.Eckroate J, Chagpar A, Hofstatter E. Breast cancer risk perception and adherence to u.s. cancer prevention guidelines. Journal Of Clinical Oncology 2018, 36: 1554-1554. DOI: 10.1200/jco.2018.36.15_suppl.1554.
  • Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.
  • The effect of black cohosh on Ki67 levels in DCIS patients.Hofstatter E, Trant A, Stavris K, Horowitz N, Killelea B, Lannin D, Neumeister V, Rimm D, Chagpar A. The effect of black cohosh on Ki67 levels in DCIS patients. Journal Of Clinical Oncology 2018, 36: e13541-e13541. DOI: 10.1200/jco.2018.36.15_suppl.e13541.
  • Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancerHofstatter E, Zhu Y, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Hatzis C, Patwardhan G, Von Wahlde M, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer Cancer Research 2018, 78: p2-04-02-p2-04-02. DOI: 10.1158/1538-7445.sabcs17-p2-04-02.
  • Surgical Management of the BreastChagpar A. Surgical Management of the Breast 2018 DOI: 10.2310/7800.16006.
  • Surgical Management of the BreastChagpar A. Surgical Management of the Breast 2018 DOI: 10.2310/cgso.16006.
  • Margins and Breast CancerChagpar A. Margins and Breast Cancer 2017, 59-69. DOI: 10.1007/978-3-319-60336-0_5.
  • Abstract 5321: Metabolomics and body mass index among breast cancer survivors in The Lifestyle, Exercise, and Nutrition (LEAN) StudyFerrucci L, Cartmel B, Harrigan M, Sanft T, Playdon M, Jia W, Yu H, Johnson C, Pusztai L, Chagpar A, Irwin M. Abstract 5321: Metabolomics and body mass index among breast cancer survivors in The Lifestyle, Exercise, and Nutrition (LEAN) Study Cancer Research 2017, 77: 5321-5321. DOI: 10.1158/1538-7445.am2017-5321.
  • Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.
  • Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.
  • Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer.Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.
  • Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancerLigibel J, Giobbie-Hurder A, Dillion D, Shockro L, Campbell N, Rhei E, Troyan S, Dominici L, Golshan M, Chagpar A, Yung R, Freedman R, Tolaney S, Winer E, Frank E, McTiernan A, Irwin M. Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer Cancer Research 2017, 77: p5-11-02-p5-11-02. DOI: 10.1158/1538-7445.sabcs16-p5-11-02.
  • Abstract P3-10-01: Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and TobagoParkinson G, Chagpar A, Hofstatter E, Nunez-Smith M. Abstract P3-10-01: Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago Cancer Research 2017, 77: p3-10-01-p3-10-01. DOI: 10.1158/1538-7445.sabcs16-p3-10-01.
  • Abstract C22: Race does not influence outcome in triple negative breast cancerButler S, Chagpar A. Abstract C22: Race does not influence outcome in triple negative breast cancer Cancer Epidemiology Biomarkers & Prevention 2017, 26: c22-c22. DOI: 10.1158/1538-7755.disp16-c22.
  • Predictors of Weight Change in Breast Cancer Survivors: The Lifestyle, Exercise and Nutrition (LEAN) Randomized Weight Loss TrialHarrigan M, Playdon M, Cartmel B, Loftfield E, Sanft T, Chagpar A, Zhou Y, Anderson C, Pusztai L, Irwin M. Predictors of Weight Change in Breast Cancer Survivors: The Lifestyle, Exercise and Nutrition (LEAN) Randomized Weight Loss Trial Journal Of The Academy Of Nutrition And Dietetics 2016, 116: a90. DOI: 10.1016/j.jand.2016.06.326.
  • Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer.Ligibel J, Giobbie-Hurder A, Shockro L, Rhei E, Troyan S, Dominici L, Chagpar A, Frank E, McTiernan A, Yung R, Freedman R, Tolaney S, O'Connor K, Stecker K, Dillon D, Irwin M. Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer. Journal Of Clinical Oncology 2016, 34: 564-564. DOI: 10.1200/jco.2016.34.15_suppl.564.
  • Abstract P3-08-01: Randomized controlled trial of weight loss vs. usual care on telomere length in women with breast cancer: The lifestyle, exercise and nutrition (LEAN) studySanft T, Lu L, Harrigan M, Cartmel B, Zhou Y, Chagpar A, Pusztai L, Irwin M. Abstract P3-08-01: Randomized controlled trial of weight loss vs. usual care on telomere length in women with breast cancer: The lifestyle, exercise and nutrition (LEAN) study Cancer Research 2016, 76: p3-08-01-p3-08-01. DOI: 10.1158/1538-7445.sabcs15-p3-08-01.
  • Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trialChagpar A, Longley P, Horowitz N, Killelea B, Tsangaris T, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin D, Pusztai L, Loftus M, Davidoff A, Gross C. Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial Cancer Research 2016, 76: p3-13-01-p3-13-01. DOI: 10.1158/1538-7445.sabcs15-p3-13-01.
  • Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarkerMani N, Schalper K, Hatzis C, Chagpar A, Pusztai L, Rimm D. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker Cancer Research 2016, 76: p5-07-09-p5-07-09. DOI: 10.1158/1538-7445.sabcs15-p5-07-09.
  • Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancerKillelea B, Chagpar A, Horowitz N, Pusztai L, Wang S, Mougalian S, Lannin D. Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer Cancer Research 2016, 76: p1-09-01-p1-09-01. DOI: 10.1158/1538-7445.sabcs15-p1-09-01.
  • Surgical Margins and Minimizing the Need for Re-excisionChagpar A. Surgical Margins and Minimizing the Need for Re-excision Breast Diseases A Year Book Quarterly 2016, 27: 186-188. DOI: 10.1016/j.breastdis.2016.07.027.
  • Collective Wisdom: Lobular Carcinoma of the BreastSledge G, Chagpar A, Perou C. Collective Wisdom: Lobular Carcinoma of the Breast American Society Of Clinical Oncology Educational Book 2016, 36: 18-21. DOI: 10.14694/edbk_100002.
  • Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011Killelea B, Chagpar A, Horowitz N, Lannin D. Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011 Journal Of The American College Of Surgeons 2015, 221: e4. DOI: 10.1016/j.jamcollsurg.2015.08.310.
  • Abstract B75: Factors correlated with follow up after an abnormal mammogram: A population-based studyLightbourne T, Chagpar A. Abstract B75: Factors correlated with follow up after an abnormal mammogram: A population-based study Cancer Epidemiology Biomarkers & Prevention 2015, 24: b75-b75. DOI: 10.1158/1538-7755.disp14-b75.
  • Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).Chagpar A, Killelea B, Tsangaris T, Butler M, Stavris K, Yao X, Li F, Bossuyt V, Pusztai L, Horowitz N. Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM). Journal Of Clinical Oncology 2015, 33: 1012-1012. DOI: 10.1200/jco.2015.33.15_suppl.1012.
  • Distress in cancer survivors attending a multidisciplinary survivorship clinic.Sanft T, Epstein L, Capozza S, Harrigan M, Jauk M, Khairallah A, Jorge J, Sokoloff L, Chen S, Chagpar A, Irwin M. Distress in cancer survivors attending a multidisciplinary survivorship clinic. Journal Of Clinical Oncology 2015, 33: 9575-9575. DOI: 10.1200/jco.2015.33.15_suppl.9575.
  • Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.Timms K, Chagpar A, Wali V, Bossuyt V, Reid J, Gutin A, Neff C, Hofstatter E, Lanchbury J, Pusztai L. Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. Journal Of Clinical Oncology 2015, 33: 1091-1091. DOI: 10.1200/jco.2015.33.15_suppl.1091.
  • Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsiesShi W, Chagpar A, Jiang T, Lannin D, Killelea B, Horowitz N, Lim R, Platt J, Ng C, Wali V, Weigelt B, Reis-Filho J, Hatzis C, Pusztai L. Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies 2015, pd3-4-pd3-4. DOI: 10.1158/1538-7445.sabcs14-pd3-4.
  • Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer DatabaseChagpar A, Mougalian S, Lannin D, Abu-Khalaf M, Killelea B, Sanft T, Pusztai L. Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database 2015, p3-07-11-p3-07-11. DOI: 10.1158/1538-7445.sabcs14-p3-07-11.
  • Abstract P3-07-19: Breast cancer risk perception and adherence to U.S. cancer prevention guidelinesHofstatter E, Chagpar A. Abstract P3-07-19: Breast cancer risk perception and adherence to U.S. cancer prevention guidelines 2015, p3-07-19-p3-07-19. DOI: 10.1158/1538-7445.sabcs14-p3-07-19.
  • Abstract P4-12-11: Patient perceptions of the impact of genetic testing for breast cancer risk on health insuranceHofstatter E, Chagpar A. Abstract P4-12-11: Patient perceptions of the impact of genetic testing for breast cancer risk on health insurance 2015, p4-12-11-p4-12-11. DOI: 10.1158/1538-7445.sabcs14-p4-12-11.
  • Abstract P3-11-02: Predictors of complete pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011Yang V, Han G, Mougalian S, Killelea B, Horowitz N, Chagpar A, Hayse B, Pusztai L, Lannin D. Abstract P3-11-02: Predictors of complete pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011 2015, p3-11-02-p3-11-02. DOI: 10.1158/1538-7445.sabcs14-p3-11-02.
  • Abstract P5-03-01: Breast cancer biology varies dramatically by method of detection and may account for overdiagnosisHayse B, Kanumuri P, Killelea B, Horowitz N, Chagpar A, Lannin D. Abstract P5-03-01: Breast cancer biology varies dramatically by method of detection and may account for overdiagnosis 2015, p5-03-01-p5-03-01. DOI: 10.1158/1538-7445.sabcs14-p5-03-01.
  • Epidemiology of Ductal Carcinoma In SituKanumuri P, Chagpar A. Epidemiology of Ductal Carcinoma In Situ 2015, 1-11. DOI: 10.1007/978-1-4939-2035-8_1.
  • Surgical Management of Hereditary Breast CancerPlasilova M, Chagpar A. Surgical Management of Hereditary Breast Cancer Current Breast Cancer Reports 2015, 7: 43-47. DOI: 10.1007/s12609-014-0169-5.
  • Access to Breast Reconstruction After Mastectomy and Patient Perspectives on Reconstruction Decision Making Morrow M, Li Y, Alderman AK, et al (Memorial Sloan Kettering Cancer Ctr, NY; Univ of Michigan, Ann Arbor; The Swan Ctr for Plastic Surgery, Alpharetta, GA; et al) JAMA Surg 149:1015-1021, 2014§Chagpar A. Access to Breast Reconstruction After Mastectomy and Patient Perspectives on Reconstruction Decision Making Morrow M, Li Y, Alderman AK, et al (Memorial Sloan Kettering Cancer Ctr, NY; Univ of Michigan, Ann Arbor; The Swan Ctr for Plastic Surgery, Alpharetta, GA; et al) JAMA Surg 149:1015-1021, 2014§ Breast Diseases A Year Book Quarterly 2015, 26: 153-154. DOI: 10.1016/j.breastdis.2015.04.024.
  • Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?Chagpar A, Butler M, Killelea B, Horowitz N, Stavris K, Lannin D. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? Journal Of Clinical Oncology 2014, 32: 107-107. DOI: 10.1200/jco.2014.32.30_suppl.107.
  • Factors correlated with HPV vaccination in the LGBT community.Anders A, Chagpar A. Factors correlated with HPV vaccination in the LGBT community. Journal Of Clinical Oncology 2014, 32: 202-202. DOI: 10.1200/jco.2014.32.30_suppl.202.
  • Abstract 5039: Physical activity is associated with improved quality of life in cancer survivors: A population-based analysisTewari A, Irwin M, Chagpar A. Abstract 5039: Physical activity is associated with improved quality of life in cancer survivors: A population-based analysis 2014, 5039-5039. DOI: 10.1158/1538-7445.am2014-5039.
  • A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes Canavese G, Bruzzi P, Catturich A, et al (IRCCS-AOU San Martino – IST, Genova, Italy) Eur J Surg Oncol 40:835-842, 2014§Chagpar A. A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes Canavese G, Bruzzi P, Catturich A, et al (IRCCS-AOU San Martino – IST, Genova, Italy) Eur J Surg Oncol 40:835-842, 2014§ Breast Diseases A Year Book Quarterly 2014, 25: 332-333. DOI: 10.1016/j.breastdis.2014.10.007.
  • 7 The axilla current management including sentinel node and lymphoedemaChagpar A. 7 The axilla current management including sentinel node and lymphoedema 2014, 109-126. DOI: 10.1016/b978-0-7020-4959-0.00007-2.
  • Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receiptRutter C, Mancini B, Gross C, Aminawung J, Chagpar A, Saglam O, Hofstatter E, Abu-Khalaf M, Evans S. Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receipt Cancer Research 2013, 73: p2-11-22-p2-11-22. DOI: 10.1158/0008-5472.sabcs13-p2-11-22.
  • Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypesHatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes Cancer Research 2013, 73: p6-06-37-p6-06-37. DOI: 10.1158/0008-5472.sabcs13-p6-06-37.
  • Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United StatesMougalian S, Abu-Khalaf M, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States Cancer Research 2013, 73: p3-14-02-p3-14-02. DOI: 10.1158/0008-5472.sabcs13-p3-14-02.
  • Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United StatesHofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A. Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United States Cancer Research 2013, 73: p5-13-05-p5-13-05. DOI: 10.1158/0008-5472.sabcs13-p5-13-05.
  • Abstract P5-13-04: What’s your excuse?: Reasons women with a first degree family history of breast cancer don’t get mammogramsHibler L, Hofstatter E, Chagpar A. Abstract P5-13-04: What’s your excuse?: Reasons women with a first degree family history of breast cancer don’t get mammograms Cancer Research 2013, 73: p5-13-04-p5-13-04. DOI: 10.1158/0008-5472.sabcs13-p5-13-04.
  • Abstract B59: Bilateral oophorectomy at age 55 or older does not reduce risk of breast cancerHofstatter E, Chagpar A. Abstract B59: Bilateral oophorectomy at age 55 or older does not reduce risk of breast cancer Cancer Prevention Research 2013, 6: b59-b59. DOI: 10.1158/1940-6215.prev-13-b59.
  • Factors associated with unplanned breast cancer readmissions.Gavankar C, Gross C, Lilenbaum R, Chagpar A. Factors associated with unplanned breast cancer readmissions. Journal Of Clinical Oncology 2013, 31: 131-131. DOI: 10.1200/jco.2013.31.31_suppl.131.
  • Abstract C08: Disclosure and cancer screening rates among lesbian, gay, bisexual and transgender (LGBT) populationsOng C, Winer J, Patridge E, Dai F, Margolies L, Chagpar A. Abstract C08: Disclosure and cancer screening rates among lesbian, gay, bisexual and transgender (LGBT) populations Cancer Prevention Research 2013, 6: c08-c08. DOI: 10.1158/1940-6215.prev-13-c08.
  • Trial Design: Overview of Study Designs (Phase I, II, III, IV, Factorial Design)Killelea B, Chagpar A. Trial Design: Overview of Study Designs (Phase I, II, III, IV, Factorial Design) 2013, 169-177. DOI: 10.1007/978-1-4471-4679-7_14.
  • The impact of survivorship care plans on knowledge among breast cancer survivors.Bulloch K, Irwin M, Chagpar A, Horowitz N, Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. DOI: 10.1200/jco.2013.31.26_suppl.124.
  • Does removal of DCIS decrease the incidence of invasive breast cancer?Killelea B, Christy C, Horowitz N, Tsangaris T, Dixon M, Chagpar A, Grube B, Lannin D. Does removal of DCIS decrease the incidence of invasive breast cancer? Journal Of Clinical Oncology 2013, 31: 2-2. DOI: 10.1200/jco.2013.31.26_suppl.2.
  • Public awareness of the HPV vaccine: A national population-based study.Shrader A, Niccolai L, Mayne S, DiMaio D, Chagpar A. Public awareness of the HPV vaccine: A national population-based study. Journal Of Clinical Oncology 2013, 31: 1574-1574. DOI: 10.1200/jco.2013.31.15_suppl.1574.
  • A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.Hofstatter E, Stavris K, Horowitz N, Killelea B, Tsangaris T, Lannin D, Andrejeva L, Cong X, Yao X, Rimm D, Chagpar A. A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ. Journal Of Clinical Oncology 2013, 31: tps1609-tps1609. DOI: 10.1200/jco.2013.31.15_suppl.tps1609.
  • Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study.Sinclair N, Sakr B, Abu-Khalaf M, Somlo G, Black R, Chung G, Rizack T, Strenger R, Fenton M, DiGiovanna M, Constantinou M, Lannin D, Legare R, Chagpar A, Sambandam S, Bossuyt V, Rosati K, Harris L, Sikov W. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study. Journal Of Clinical Oncology 2013, 31: 619-619. DOI: 10.1200/jco.2013.31.15_suppl.619.
  • Awareness of HPV and its vaccine among lesbian, gay, bisexual, transgender, and queer (LGBTQ) populations.Ong C, Winer J, Margolies L, Dai F, Patridge E, Chagpar A. Awareness of HPV and its vaccine among lesbian, gay, bisexual, transgender, and queer (LGBTQ) populations. Journal Of Clinical Oncology 2013, 31: e17597-e17597. DOI: 10.1200/jco.2013.31.15_suppl.e17597.
  • SHAVE: A randomized controlled trial of routine shave margins versus standard partial mastectomy.Chagpar A, Stavris K, Killelea B, Tsangaris T, Horowitz N. SHAVE: A randomized controlled trial of routine shave margins versus standard partial mastectomy. Journal Of Clinical Oncology 2013, 31: tps1145-tps1145. DOI: 10.1200/jco.2013.31.15_suppl.tps1145.
  • Do nonmelanoma skin cancer survivors use tanning beds more often than the general public?Wiznia L, Ferrucci L, Mayne S, Chagpar A. Do nonmelanoma skin cancer survivors use tanning beds more often than the general public? Journal Of Clinical Oncology 2013, 31: e20017-e20017. DOI: 10.1200/jco.2013.31.15_suppl.e20017.
  • Abstract 1365: Sun protection practices among melanoma survivors.Puthumana J, Ferrucci L, Mayne S, Lannin D, Chagpar A. Abstract 1365: Sun protection practices among melanoma survivors. Cancer Research 2013, 73: 1365-1365. DOI: 10.1158/1538-7445.am2013-1365.
  • State of the Art in Imaging and Chemoprevention for High-Risk PatientsHofstatter E, Andrejeva L, Chagpar A. State of the Art in Imaging and Chemoprevention for High-Risk Patients Current Breast Cancer Reports 2013, 5: 125-133. DOI: 10.1007/s12609-013-0104-1.
  • The Prognostic Implications of Histologic Subtype of Ductal Carcinoma in SituSue G, Lannin D, Killelea B, Horowitz N, Tsangaris T, Chagpar A. The Prognostic Implications of Histologic Subtype of Ductal Carcinoma in Situ Journal Of Surgical Research 2013, 179: 193. DOI: 10.1016/j.jss.2012.10.224.
  • Abstract P2-11-08: Feasibility of Enrollment Into a Survivorship Care Plan Study at Initial DiagnosisBulloch K, Irwin M, Chagpar A, Sanft T. Abstract P2-11-08: Feasibility of Enrollment Into a Survivorship Care Plan Study at Initial Diagnosis Cancer Research 2012, 72: p2-11-08-p2-11-08. DOI: 10.1158/0008-5472.sabcs12-p2-11-08.
  • Abstract P3-14-05: Recurrence in Patients Diagnosed with Ductal Carcinoma in Situ: Predictors and Prognostic SignificanceSue G, Killelea B, Horowitz N, Lannin D, Chagpar A. Abstract P3-14-05: Recurrence in Patients Diagnosed with Ductal Carcinoma in Situ: Predictors and Prognostic Significance Cancer Research 2012, 72: p3-14-05-p3-14-05. DOI: 10.1158/0008-5472.sabcs12-p3-14-05.
  • Abstract P3-14-06: The Utility of Margin Index to Predict Residual DCIS Following Breast Conserving SurgeryAneja S, Lannin D, Killelea B, Horowitz N, Chagpar A. Abstract P3-14-06: The Utility of Margin Index to Predict Residual DCIS Following Breast Conserving Surgery Cancer Research 2012, 72: p3-14-06-p3-14-06. DOI: 10.1158/0008-5472.sabcs12-p3-14-06.
  • Understanding Costs and Value of Newer Radiation Modalities Among Older Women With Breast CancerSen S, Soulos P, Frick K, Long J, Roberts K, Yu J, Evans S, Chagpar A, Gross C. Understanding Costs and Value of Newer Radiation Modalities Among Older Women With Breast Cancer International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s35. DOI: 10.1016/j.ijrobp.2012.07.096.
  • Predictors of residual disease after breast-conserving surgery.Aneja S, Lannin D, Killelea B, Horowitz N, Chagpar A. Predictors of residual disease after breast-conserving surgery. Journal Of Clinical Oncology 2012, 30: 168-168. DOI: 10.1200/jco.2012.30.27_suppl.168.
  • Predictors of microinvasion and its prognostic role in ductal carcinoma in situ.Sue G, Lannin D, Killelea B, Horowitz N, Chagpar A. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Journal Of Clinical Oncology 2012, 30: 188-188. DOI: 10.1200/jco.2012.30.27_suppl.188.
  • Breast cancer and socio-economic factorsChagpar A, Coccia M. Breast cancer and socio-economic factors Working Paper Of Public Health 2012, 1 DOI: 10.4081/wpph.2012.6773.
  • The evolution of breast cancer screening in the Medicare population: Clinical and economic implications.Killelea B, Long J, Ma X, Wang R, Chagpar A, Ross J, Gross C. The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. Journal Of Clinical Oncology 2012, 30: 1595-1595. DOI: 10.1200/jco.2012.30.15_suppl.1595.
  • Accuracy of breast MRI in predicting pathologic tumor size.Caprio K, Caprio K, Chagpar A, Hooley R, Tavassoli F, Honarpishe H, Honarpishe H, Lannin D, Killelea B, Killelea B, Horowitz N, Horowitz N. Accuracy of breast MRI in predicting pathologic tumor size. Journal Of Clinical Oncology 2012, 30: 1109-1109. DOI: 10.1200/jco.2012.30.15_suppl.1109.
  • Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.
  • The effect of family history on adherence to breast cancer screening guidelines.Hibler L, Chagpar A. The effect of family history on adherence to breast cancer screening guidelines. Journal Of Clinical Oncology 2012, 30: 1571-1571. DOI: 10.1200/jco.2012.30.15_suppl.1571.
  • Do Health Care Professionals Discuss the Emotional Impact of Cancer with Patients?Bonito A, Horowitz N, McCorkle R, Chagpar A. Do Health Care Professionals Discuss the Emotional Impact of Cancer with Patients? Journal Of Surgical Research 2012, 172: 343. DOI: 10.1016/j.jss.2011.11.747.
  • Defining HIV Risk in the Surgical PopulationAdewole A, Chagpar A. Defining HIV Risk in the Surgical Population Journal Of Surgical Research 2012, 172: 189. DOI: 10.1016/j.jss.2011.11.061.
  • Accuracy of sentinel lymph node biopsy in large and multifocal/multicentric breast carcinoma—A systematic review Spillane AJ, Brennan ME (Breast and Surgical Oncology at The Poche Centre, North Sydney, New South Wales, Australia) Eur J Surg Oncol 37:371-385, 2011§Chagpar A. Accuracy of sentinel lymph node biopsy in large and multifocal/multicentric breast carcinoma—A systematic review Spillane AJ, Brennan ME (Breast and Surgical Oncology at The Poche Centre, North Sydney, New South Wales, Australia) Eur J Surg Oncol 37:371-385, 2011§ Breast Diseases A Year Book Quarterly 2012, 23: 71-72. DOI: 10.1016/j.breastdis.2012.01.040.
  • P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior?Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters K, Sephton S, Chagpar A. P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior? Cancer Research 2011, 71: p1-01-15-p1-01-15. DOI: 10.1158/0008-5472.sabcs11-p1-01-15.
  • P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast.Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar A. P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast. Cancer Research 2011, 71: p3-05-08-p3-05-08. DOI: 10.1158/0008-5472.sabcs11-p3-05-08.
  • P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11?Lannin D, Killelea B, Grube B, Horowitz N, Chagpar A. P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11? Cancer Research 2011, 71: p3-07-26-p3-07-26. DOI: 10.1158/0008-5472.sabcs11-p3-07-26.
  • Who provides ongoing care to breast cancer survivors and does it make a difference?Sowden M, Sanft T, Chagpar A. Who provides ongoing care to breast cancer survivors and does it make a difference? Journal Of Clinical Oncology 2011, 29: 199-199. DOI: 10.1200/jco.2011.29.27_suppl.199.
  • Factors affecting lymphovascular invasion in node-positive breast cancer patients.Cornwell L, McMasters K, Chagpar A. Factors affecting lymphovascular invasion in node-positive breast cancer patients. Journal Of Clinical Oncology 2011, 29: 24-24. DOI: 10.1200/jco.2011.29.27_suppl.24.
  • Do cancer survivors follow screening guidelines better?Chagpar A, Sanft T, Gross C. Do cancer survivors follow screening guidelines better? Journal Of Clinical Oncology 2011, 29: 1597-1597. DOI: 10.1200/jco.2011.29.15_suppl.1597.
  • Agreement between breast cancer survivors and oncologists on treatments received.Sanft T, Northrup V, Chagpar A, Irwin M. Agreement between breast cancer survivors and oncologists on treatments received. Journal Of Clinical Oncology 2011, 29: 9106-9106. DOI: 10.1200/jco.2011.29.15_suppl.9106.
  • Acute Toxicity and Early Cosmetic Outcome in Patients Treated With Multicatheter Balloon Brachytherapy With Skin Spacing ≤7.0 MillimetersLee K, Sowards K, Dillon D, Hatmaker A, Brown C, Quillo A, Chagpar A, Dragun A. Acute Toxicity and Early Cosmetic Outcome in Patients Treated With Multicatheter Balloon Brachytherapy With Skin Spacing ≤7.0 Millimeters Brachytherapy 2011, 10: s46. DOI: 10.1016/j.brachy.2011.02.072.
  • How Can the AJCC Staging System Be Improved?Chagpar A. How Can the AJCC Staging System Be Improved? Current Breast Cancer Reports 2011, 3: 104-108. DOI: 10.1007/s12609-011-0041-9.
  • Factors Affecting Lymph Node Ratio In Breast Cancer PatientsCornwell L, Chagpar A, McMasters K. Factors Affecting Lymph Node Ratio In Breast Cancer Patients Journal Of Surgical Research 2011, 165: 179. DOI: 10.1016/j.jss.2010.11.743.
  • Factors Affecting Survival Following First Locoregional Recurrence After Surgically Managed Breast CancerCrutcher C, Chagpar A. Factors Affecting Survival Following First Locoregional Recurrence After Surgically Managed Breast Cancer Journal Of Surgical Research 2011, 165: 178. DOI: 10.1016/j.jss.2010.11.737.
  • Intraoperative Considerations in Sentinel Lymph Node Biopsy for Breast CancerChagpar A. Intraoperative Considerations in Sentinel Lymph Node Biopsy for Breast Cancer Oncology & Hematology Review (US) 2011, 07: 111. DOI: 10.17925/ohr.2011.07.2.111.
  • Abstract P2-12-01: Is Cancer-Specific Distress Correlated with Time to Definitive Surgery in Breast Cancer Patients?Daup M, Lush E, Dedert E, McMasters K, Sephton S, Chagpar A. Abstract P2-12-01: Is Cancer-Specific Distress Correlated with Time to Definitive Surgery in Breast Cancer Patients? Cancer Research 2010, 70: p2-12-01-p2-12-01. DOI: 10.1158/0008-5472.sabcs10-p2-12-01.
  • Abstract P3-10-10: Progesterone Receptor-Negative Status Predicts Poorer Outcomes in Estrogen Receptor-Positive Patients Treated with Selective Estrogen Receptor ModulatorsChagpar A, McMasters K, Edwards M. Abstract P3-10-10: Progesterone Receptor-Negative Status Predicts Poorer Outcomes in Estrogen Receptor-Positive Patients Treated with Selective Estrogen Receptor Modulators Cancer Research 2010, 70: p3-10-10-p3-10-10. DOI: 10.1158/0008-5472.sabcs10-p3-10-10.
  • Effect of surgical treatment of primary tumor on outcome in stage IV breast cancer.Bower M, Brown R, Scoggins C, McMasters K, Chagpar A. Effect of surgical treatment of primary tumor on outcome in stage IV breast cancer. Journal Of Clinical Oncology 2010, 28: 1103-1103. DOI: 10.1200/jco.2010.28.15_suppl.1103.
  • Abstract 1701: Elevated DNA adducts detected in human breast tumors than normal tissues from mammoplastyMungala R, Vadhanam M, Chagpar A, Fleming M, Fink B, Gridley M, Vasconez H, Gupta R. Abstract 1701: Elevated DNA adducts detected in human breast tumors than normal tissues from mammoplasty Cancer Research 2010, 70: 1701-1701. DOI: 10.1158/1538-7445.am10-1701.
  • Factors Influencing Reconstruction after Bilateral MastectomySmith S, Nasser S, Chagpar A. Factors Influencing Reconstruction after Bilateral Mastectomy Journal Of Surgical Research 2010, 158: 264. DOI: 10.1016/j.jss.2009.11.262.
  • Sentinel Lymph Node Biopsy May Not Be Necessary in All Patients Undergoing Prophylactic Mastectomy But Should Be Considered in Patients with Inflammatory Breast Cancer and/or Extensive Ipsilateral Axillary DiseaseNasser S, Smith S, Chagpar A. Sentinel Lymph Node Biopsy May Not Be Necessary in All Patients Undergoing Prophylactic Mastectomy But Should Be Considered in Patients with Inflammatory Breast Cancer and/or Extensive Ipsilateral Axillary Disease Journal Of Surgical Research 2010, 158: 263-264. DOI: 10.1016/j.jss.2009.11.260.
  • Can Sentinel Node Biopsy Be Avoided in Some Elderly Breast Cancer Patients?Chagpar A, McMasters K, Edwards M. Can Sentinel Node Biopsy Be Avoided in Some Elderly Breast Cancer Patients? Annals Of Surgery 2010, 251: 181-182. DOI: 10.1097/sla.0b013e3181c77039.
  • Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes.Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Mamounas E, Giuliano A, Cook E, Wang S. Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes. Cancer Research 2009, 69: 302-302. DOI: 10.1158/0008-5472.sabcs-09-302.
  • Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN)Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Saha S, Julian T. Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN) Journal Of Clinical Oncology 2009, 27: 530-530. DOI: 10.1200/jco.2009.27.15_suppl.530.
  • Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patientsReuter N, Bower M, Scoggins C, Martin R, McMasters K, Chagpar A. Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients Journal Of Clinical Oncology 2009, 27: 611-611. DOI: 10.1200/jco.2009.27.15_suppl.611.
  • Prediction of Thromboembolic Events in Women with Hormone Receptor-Positive Breast Cancer Receiving SERMSLewis J, Chagpar A, McMasters K, Edwards M. Prediction of Thromboembolic Events in Women with Hormone Receptor-Positive Breast Cancer Receiving SERMS Journal Of Surgical Research 2009 DOI: 10.1016/j.jss.2009.03.089.
  • QS103. Quantitative Galactose Oxidase Schiff Reaction in Nipple Aspirate Fluid May Distinguish Women With or Without Breast CancerChagpar A, Clements K, Carte C, McMasters K, Evelegh M. QS103. Quantitative Galactose Oxidase Schiff Reaction in Nipple Aspirate Fluid May Distinguish Women With or Without Breast Cancer Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.399.
  • QS112. Trends in Surgical Management of Early Breast CancerChagpar A, McMasters K. QS112. Trends in Surgical Management of Early Breast Cancer Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.408.
  • QS116. Malignant Phylloides Tumor in the First Trimester of PregnancyBlaker K, Sahoo S, Schweichler M, Chagpar A. QS116. Malignant Phylloides Tumor in the First Trimester of Pregnancy Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.412.
  • QS109. Validation of a Clinical Prediction Rule for Patients' Likelihood of Requiring Post-Mastectomy Radiation TherapyChagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Giuliano A, McMasters K, Mamounas E. QS109. Validation of a Clinical Prediction Rule for Patients' Likelihood of Requiring Post-Mastectomy Radiation Therapy Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.405.
  • QS120. Trends in Genetic Testing in the United StatesChagpar A, McMasters K. QS120. Trends in Genetic Testing in the United States Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.416.
  • 18. Prediction of Thromboembolic Events in Women With Hormone Receptor-Positive Breast Cancer Receiving SERMsLewis J, Chagpar A, McMasters K, Edwards M. 18. Prediction of Thromboembolic Events in Women With Hormone Receptor-Positive Breast Cancer Receiving SERMs Journal Of Surgical Research 2009, 151: 179. DOI: 10.1016/j.jss.2008.11.033.
  • Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer.Chagpar A, Lewis J, McMasters K, Edwards M. Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer. Cancer Research 2009, 69: 4105. DOI: 10.1158/0008-5472.sabcs-4105.
  • Internal Mammary Nodal Chain Drainage Is a Prognostic Indicator in Axillary Node-Positive Breast CancerChagpar A. Internal Mammary Nodal Chain Drainage Is a Prognostic Indicator in Axillary Node-Positive Breast Cancer Breast Diseases A Year Book Quarterly 2008, 19: 147-148. DOI: 10.1016/s1043-321x(08)80094-x.
  • Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patientsChagpar A. Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients Breast Diseases A Year Book Quarterly 2008, 19: 159. DOI: 10.1016/s1043-321x(08)80104-x.
  • Use of adjuvant chemotherapy in young women with node-negative ER+ breast cancer: Refining the use of recurrence score—A decision analysisWoodall C, Reuter N, Scoggins C, Martin R, McMasters K, Hargis J, Chagpar A. Use of adjuvant chemotherapy in young women with node-negative ER+ breast cancer: Refining the use of recurrence score—A decision analysis Journal Of Clinical Oncology 2008, 26: 11547-11547. DOI: 10.1200/jco.2008.26.15_suppl.11547.
  • QS132. Racial Trends in Mammography Rates: A Population-Based StudyChagpar A, Polk H, McMasters K. QS132. Racial Trends in Mammography Rates: A Population-Based Study Journal Of Surgical Research 2008, 144: 320. DOI: 10.1016/j.jss.2007.12.372.
  • QS127. Response of Axillary Lymph Nodes to Neoadjuvant Chemotherapy Parallels Primary Tumor Response in Breast Cancer PatientsPilavas J, Napper L, Clements K, Chagpar A. QS127. Response of Axillary Lymph Nodes to Neoadjuvant Chemotherapy Parallels Primary Tumor Response in Breast Cancer Patients Journal Of Surgical Research 2008, 144: 318. DOI: 10.1016/j.jss.2007.12.367.
  • Distant Metastasis in Elderly Patients with Breast Cancer: Prognosis with Nodal StatusChagpar A. Distant Metastasis in Elderly Patients with Breast Cancer: Prognosis with Nodal Status 2008, 1: 601-608. DOI: 10.1007/978-1-4020-8369-3_42.
  • 3–36 Risk Factors for Non-Sentinel Lymph Node Metastases in Patients with Breast Cancer. The Outcome of a Multi-institutional StudyChagpar A. 3–36 Risk Factors for Non-Sentinel Lymph Node Metastases in Patients with Breast Cancer. The Outcome of a Multi-institutional Study Breast Diseases A Year Book Quarterly 2007, 18: 279-280. DOI: 10.1016/s1043-321x(07)80331-6.
  • 3–42 A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate NomogramChagpar A. 3–42 A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram Breast Diseases A Year Book Quarterly 2007, 18: 285. DOI: 10.1016/s1043-321x(07)80338-9.
  • 2–37 Sentinel Lymph Node Biopsy for Local Recurrence of Breast Cancer After Breast-Conserving TherapyChagpar A. 2–37 Sentinel Lymph Node Biopsy for Local Recurrence of Breast Cancer After Breast-Conserving Therapy Breast Diseases A Year Book Quarterly 2007, 18: 177. DOI: 10.1016/s1043-321x(07)80240-2.
  • What caused the decline in breast cancer incidence rates?Chagpar A, McMasters K. What caused the decline in breast cancer incidence rates? Journal Of Clinical Oncology 2007, 25: 1513-1513. DOI: 10.1200/jco.2007.25.18_suppl.1513.
  • P219 Trends in mammography and clinical breast examination: Results of a national population-based surveyChagpar A, Scoggins C, Martin R, McMasters K. P219 Trends in mammography and clinical breast examination: Results of a national population-based survey Journal Of Surgical Research 2007, 137: 319-320. DOI: 10.1016/j.jss.2006.12.403.
  • Breast-Conserving Surgery After Chemotherapy: Value of MDCT for Determining Tumor Distribution and Shrinkage PatternChagpar A. Breast-Conserving Surgery After Chemotherapy: Value of MDCT for Determining Tumor Distribution and Shrinkage Pattern Breast Diseases A Year Book Quarterly 2006, 17: 262. DOI: 10.1016/s1043-321x(06)80521-7.
  • Lymphoscintigraphy and Sentinel Lymph Node Biopsy of the Internal Mammary Nodes: Is It Worth It?Chagpar A. Lymphoscintigraphy and Sentinel Lymph Node Biopsy of the Internal Mammary Nodes: Is It Worth It? Breast Diseases A Year Book Quarterly 2006, 17: 131-132. DOI: 10.1016/s1043-321x(06)80409-1.
  • Perioperative Care for Breast and Gynecological NeoplasmsBrowne T, Chagpar A, Hunt K, Ramirez P. Perioperative Care for Breast and Gynecological Neoplasms 2005, 433-453. DOI: 10.1201/b14119-27.
  • 1–18 Influence of Breast Cancer Histology on the Relationship Between Ultrasound and Pathology Tumor Size MeasurementsChagpar A. 1–18 Influence of Breast Cancer Histology on the Relationship Between Ultrasound and Pathology Tumor Size Measurements Breast Diseases A Year Book Quarterly 2005, 16: 48-49. DOI: 10.1016/s1043-321x(05)80031-1.
  • 1–24 Use of Preoperative Breast Ultrasonography for Mapping of Breast Cancer Extent Improves Resection Margins During Breast Conservation SurgeryChagpar A. 1–24 Use of Preoperative Breast Ultrasonography for Mapping of Breast Cancer Extent Improves Resection Margins During Breast Conservation Surgery Breast Diseases A Year Book Quarterly 2005, 16: 55. DOI: 10.1016/s1043-321x(05)80039-6.
  • Mastitis and Breast AbscessChagpar A, Babiera G. Mastitis and Breast Abscess Problems In General Surgery 2003, 20: 27-34. DOI: 10.1097/01.sgs.0000105783.43559.6c.
  • Outcome of Breast Cancer Patients with Chest Wall RecurrenceChagpar A, Kuerer H, Hunt K, Strom E, Buchholz T. Outcome of Breast Cancer Patients with Chest Wall Recurrence The Cancer Journal 2003, 9: 507. DOI: 10.1097/00130404-200311000-00082.